Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 153   

Articles published

MRK 60.40 +0.65 (1.09%)
price chart
Merck buys rights to NewLink's experimental Ebola vaccine
(Reuters) - Merck & Co Inc (MRK.N) on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's (NLNK.
Merck acquires rights to NewLink's Ebola vaccine candidate  Seeking Alpha
Big News for Ebola Stocks  24/7 Wall St.
Related articles »  
Drug Makers Dominating Friday- Merck & Co. Inc. (NYSE:MRK), Medtronic, Inc ...
Merck & Co. Inc. (NYSE:MRK) [Detail Analytic Report] KGaA purposes to keep support of its consumer healthcare unit, it reported on Friday, promising to improve a business that is projected to make 2014 sales of $1 billion for the German drugs and ...
Trader's Buzzers: Merck & Co., Inc. (NYSE:MRK), Total SA (ADR) (NYSE ...  Techsonian (press release)
Hot Stocks: Merck & Co. Inc. (NYSE:MRK), iDreamSky Technology Limited ...  Gaining Green
Related articles »  
Merck & Co., Inc. (NYSE:MRK) Reports Results from Hepatitis C Treatment
Merck & Co., Inc. (NYSE:MRK) reported Tuesday promising results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir, a product to treat the chronic hepatitis C virus genotype 1 in treatment-naive and previously-treated patients.
Merck Reports Interim Data on Hepatitis C Virus Drug  Yahoo News
Related articles »  
Merck Shares May Have Hit A Ceiling For The Most Recent Upside Move
Merck & Co., Inc. (NYSE: MRK) stock participated in the market's recent upside like most other U.S. equity issues. However, unlike some that broke out to new highs, Merck shares seem to have "hit the wall" in terms of upside momentum at just above $60.
News Buzz � Merck & Co., Inc. (NYSE:MRK), Gilead Sciences, Inc. (NASDAQ ...  Techsonian (press release)
Merck & Co. Shares Gap Down on Insider Selling (MRK)  Mideast Time
Related articles »  
Anti-PD-1 Drug Keytruda Gives Merck & Co. (MRK) Reason To Rejoice Again
Merck & Co., Inc. (NYSE:MRK) has announced positive Phase II trial results for its anti-PD-1 therapy Keytruda (pembrolizumab).
Medical Breakthroughs On The Horizon For Merck (MRK)
Merck (MRK) is a global health care company that includes prescription medicines; vaccines, biologic therapies, animal health and consumer care products.
Merck & Co. Inc. (MRK) Tops DJIA Gainers for November 3
The Dow closed at 17,366.20 on Monday, which is a -0.14% move from yesterday's close. Merck & Co. Inc. led all gainers with a 1.69% jump.
Interesting January 2017 Stock Options for Merck & Co.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co MRK +0.69%., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »  
Interesting July 2015 Stock Options for Merck
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co MRK +1.09%., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »  
RBC Sees Weak Merck Data As Positive For Gilead
In a note from RBC Capital analyst Michael Yee, Merck & Co., Inc.'s (NYSE: MRK) weaker-than-expected data for hepatitis C is a net positive for Gilead Sciences, Inc. (NASDAQ: GILD).
Gilead Sciences Inc (GILD) And Merck & Co Inc (MRK) Fighting For 3 ...  Insider Monkey (blog)
Merck's (MRK) HCV Regimen Fails In Mid-Stage Study  Bidness ETC
Related articles »